Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With External Brain Radiation for Metastatic Carcinoma to the Brain.

Trial Profile

Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With External Brain Radiation for Metastatic Carcinoma to the Brain.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2014

At a glance

  • Drugs NSC 371331 (Primary) ; Tetrahydrouridine (Primary)
  • Indications Cancer metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Planned end date changed from 1 Mar 2011 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top